Sanofi US News
WEB6 days ago · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
WEB3 days ago · Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in the...
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB6 days ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to...
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB6 days ago · Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA) and Regeneron's (REGN.O) blockbuster drug Dupixent for patients with a chronic lung disease, commonly known...
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB6 days ago · Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD. Drug is cleared for 300,000 U.S. patients with a form of the lung disease driven by eosinophils. Wikimedia Commons. By...
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBMay 31, 2024 · Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent and itepekimab.
Regeneron and Sanofi Provide Update on Dupixent® …
WEBOct 20, 2023 · Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB(Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the...
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
WEB6 days ago · Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their chronic obstructive pulmonary disease (COPD) treatment received approval from the Food and Drug Administration...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB6 days ago · The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s inflammatory disease drug Dupixent for a common lung condition.